The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | The IFM 2012-03 trial: what will the next step be?
Xavier Leleu, MD, PhD, from the Poitiers University Hospital, Poitiers, France, discusses the IFM 2012-03 (NCT02302495) trial at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The IFM 2012-03 (NCT02302495) trial is a phase II study involving giving carfilzomib, melphalan, and prednisone (KMP) on a weekly basis in newly diagnosed, non-transplant eligible patients. It was given at a rate of 70mg/ m2 for patients under 75, and 56mg/ m2 for patients over 75, for a number of induction cycles, and then in maintenance therapy. Other studies have found that KMP has not shown superiority to bortezomib, melphalan, and prednisone (VMP). These results clash with the results of the IFM study, however, KMP will not be developed in Europe due to these results.
